Glucotrack closed a stock-for-stock merger with Lokahi Therapeutics, making Lokahi a wholly owned subsidiary and setting Lokahi's former holders to own 90% of Glucotrack on an as-converted, fully diluted basis after preferred conversion, with a 10% floor for existing holders. To fund operations and post-closing steps, Glucotrack completed a ~$4.45 million senior secured convertible bridge financing and granted first-lien security, obtained voting support for required approvals, and established a three-year equity line of up to $50 million with White Lion. The company also issued a five-year commitment warrant and entered a registration rights agreement to facilitate resale of ELOC-related securities. Management expects these actions to support liquidity, listing compliance and strategic execution following the merger.
Agreement 1: Glucotrack Merges With Lokahi Therapeutics; Former Holders to Own 90% Post-Conversion
- Agreement type: Agreement and Plan of Merger
- Counterparty: Lokahi Therapeutics
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: One-time transaction
- Reason: Combine businesses and realign capital structure
Agreement 2: Glucotrack Raises ~$4.45 Million via Senior Secured Convertible Notes and Warrants
- Agreement type: Securities Purchase Agreement for senior secured convertible notes and warrants
- Counterparty: Bridge Investors
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 9 months (notes)
- Reason: Bridge liquidity during post-merger transition
Agreement 3: Glucotrack Grants First-Lien Security to Back Bridge Notes
- Agreement type: Security Agreement securing bridge notes
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: Until notes repaid
- Reason: Secure obligations under bridge financing
Agreement 4: Glucotrack Obtains Voting Support to Approve Bridge Issuances and Capital Actions
- Agreement type: Voting Support Agreement
- Counterparty: White Lion Capital and Supporting Stockholders
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: Until required approvals obtained
- Reason: Facilitate approvals for financing and listing compliance
Agreement 5: Glucotrack Secures Up to $50 Million Equity Line With White Lion
- Agreement type: Common Stock Purchase Agreement (Equity Line of Credit)
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 3 years
- Reason: Flexible access to equity capital
Agreement 6: Glucotrack Issues Five-Year Commitment Warrant as ELOC Consideration
- Agreement type: Commitment Warrant issuance
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 5 years
- Reason: Compensate ELOC provider and align incentives
Agreement 7: Glucotrack Grants Registration Rights for ELOC, Warrant and Related Shares
- Agreement type: Registration Rights Agreement
- Counterparty: White Lion Capital
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: Until resale registration obligations satisfied
- Reason: Enable resale liquidity for issued securities
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.